{"id":"F2009L03001","name":"National Health Act 1953 - Determination under section 99ADB - weighted average disclosed price (No. PB 74 of 2009)","slug":"national-health-act-1953-determination-under-section-99adb-weighted-average-disclosed-price-no-pb-74","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":80517,"registerId":"commonwealth-F2009L03001-current","compilationNumber":null,"startDate":"2026-04-02","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health Act 1953 - Determination under section 99ADB - weighted average disclosed price (No. PB 74 of 2009)","content":"![](image.001.png)\n\nDetermination — Weighted average disclosed price (PB 74 of 2009)\n\nas amended\n\nmade under section 99ADB of the\n\nNational Health Act 1953\n\nThis compilation was prepared on 26 January 2010 \ntaking into account amendments up to PB 12 of 2010\n\nPrepared by the Office of Legislative Drafting and Publishing, \nAttorney‑General’s Department, Canberra\n\nDetermination – Weighted average disclosed price (PB 74 of 2009)\n\n1 Commencement \\[see Note 1\\]\n\nThis instrument commences on 31 July 2009.\n\n2 Repeal\n\nInstrument number PB 18 of 2009 made on 29 January 2009 with effect from 1 February 2009 is repealed.\n\n3 Determination pursuant to subsection 99ADB(4)\n\nThe weighted average disclosed price of the brands of pharmaceutical items listed in Schedule 1, is set out in column 5 of Schedule 1.\n\n4 Determination pursuant to subsection 99ADB(5)\n\nThe weighted average disclosed price of every brand of every pharmaceutical item that has the same drug and manner of administration as those brands of pharmaceutical items listed in Schedule 1, is set out in column 5 of Schedule 2\n\n```html\n

SCHEDULE 1

Listed Drug

Form (strength, type, size, etc.)

Manner of administration

Brand

Weighted average disclosed price

Carvedilol

Tablet 3.125 mg

Oral

Dilasig

$7.37

Carvedilol

Tablet 6.25 mg

Oral

Dilasig

$34.86

Carvedilol

Tablet 12.5 mg

Oral

Dilasig

$43.58

Carvedilol

Tablet 25 mg

Oral

Dilasig

$54.47

Fluconazole

Capsule 100 mg

Oral

Fluconazole Winthrop

$105.64

Fluconazole

Capsule 200 mg

Oral

Fluconazole Winthrop

$205.79

Vancomycin

Powder for injection 500 mg (500,000 i.u.) (as hydrochloride)

Injection

Vancomycin Sandoz

$4.67

Vancomycin

Powder for injection 1 g (1,000,000 i.u.) (as hydrochloride)

Injection

Vancomycin Sandoz

$9.33

\n```\n\n```html\n

SCHEDULE 2

Listed Drug

Form (strength, type, size, etc.)

Manner of administration

Brand

Weighted average disclosed price

Carvedilol

Tablet 3.125 mg

Oral

Chem mart Carvedilol 3.125 mg

$7.37

Carvedilol

Tablet 3.125 mg

Oral

Dilatrend 3.125

$7.37

Carvedilol

Tablet 3.125 mg

Oral

GenRx Carvedilol

$7.37

Carvedilol

Tablet 3.125 mg

Oral

GN-Carvedilol

$7.37

Carvedilol

Tablet 3.125 mg

Oral

Kredex

$7.37

Carvedilol

Tablet 3.125 mg

Oral

Terry White Chemists Carvedilol 3.125 mg

$7.37

Carvedilol

Tablet 3.125 mg

Oral

Vedilol 3.125

$7.37

Carvedilol

Tablet 6.25 mg

Oral

Chem mart Carvedilol 6.25 mg

$34.86

Carvedilol

Tablet 6.25 mg

Oral

Dilatrend 6.25

$34.86

Carvedilol

Tablet 6.25 mg

Oral

GenRx Carvedilol

$34.86

Carvedilol

Tablet 6.25 mg

Oral

GN-Carvedilol

$34.86

Carvedilol

Tablet 6.25 mg

Oral

Kredex

$34.86

Carvedilol

Tablet 6.25 mg

Oral

Terry White Chemists Carvedilol 6.25 mg

$34.86

Carvedilol

Tablet 6.25 mg

Oral

Vedilol 6.25

$34.86

Carvedilol

Tablet 12.5 mg

Oral

Chem mart Carvedilol 12.5 mg

$43.58

Carvedilol

Tablet 12.5 mg

Oral

Dilatrend 12.5

$43.58

Carvedilol

Tablet 12.5 mg

Oral

GenRx Carvedilol

$43.58

Carvedilol

Tablet 12.5 mg

Oral

GN-Carvedilol

$43.58

Carvedilol

Tablet 12.5 mg

Oral

Kredex

$43.58

Carvedilol

Tablet 12.5 mg

Oral

Terry White Chemists Carvedilol 12.5 mg

$43.58

Carvedilol

Tablet 12.5 mg

Oral

Vedilol 12.5

$43.58

Carvedilol

Tablet 25 mg

Oral

Chem mart Carvedilol 25 mg

$54.47

Carvedilol

Tablet 25 mg

Oral

Dilatrend 25

$54.47

Carvedilol

Tablet 25 mg

Oral

GenRx Carvedilol

$54.47

Carvedilol

Tablet 25 mg

Oral

GN-Carvedilol

$54.47

Carvedilol

Tablet 25 mg

Oral

Kredex

$54.47

Carvedilol

Tablet 25 mg

Oral

Terry White Chemists Carvedilol 25 mg

$54.47

Carvedilol

Tablet 25 mg

Oral

Vedilol 25

$54.47

Fluconazole

Capsule 50 mg

Oral

DBL Fluconazole

$54.23

Fluconazole

Capsule 50 mg

Oral

Diflucan

$54.23

Fluconazole

Capsule 50 mg

Oral

Dizole 50

$54.23

Fluconazole

Capsule 50 mg

Oral

Fluconazole Hexal

$54.23

Fluconazole

Capsule 50 mg

Oral

Fluzole 50

$54.23

Fluconazole

Capsule 50 mg

Oral

Ozole

$54.23

Fluconazole

Capsule 100 mg

Oral

DBL Fluconazole

$105.64

Fluconazole

Capsule 100 mg

Oral

Diflucan

$105.64

Fluconazole

Capsule 100 mg

Oral

Dizole 100

$105.64

Fluconazole

Capsule 100 mg

Oral

Fluconazole Hexal

$105.64

Fluconazole

Capsule 100 mg

Oral

Ozole

$105.64

Fluconazole

Capsule 200mg

Oral

APO-Fluconazole

$205.79

Fluconazole

Capsule 200 mg

Oral

DBL Fluconazole

$205.79

Fluconazole

Capsule 200 mg

Oral

Diflucan

$205.79

Fluconazole

Capsule 200 mg

Oral

Dizole 200

$205.79

Fluconazole

Capsule 200 mg

Oral

Fluconazole Hexal

$205.79

Fluconazole

Capsule 200 mg

Oral

Fluzole 200

$205.79

Fluconazole

Capsule 200 mg

Oral

Ozole

$205.79

Vancomycin

Powder for injection 500 mg (500,000 i.u.) (as hydrochloride)

Injection

Hospira Pty Limited

$4.67

Vancomycin

Powder for injection 500 mg (500,000 i.u.) (as hydrochloride)

Injection

Vancocin CP

$4.67

Vancomycin

Powder for injection 1 g (1,000,000 i.u.) (as hydrochloride)

Injection

Hospira Pty Limited

$9.33

\n```\n\n> Notes to the Determination — Weighted average disclosed price (PB 74 of 2009)\n\n> Note 1\n\n> Note: The Determination — Weighted average disclosed price (PB 74 of 2009) (in force under section 99ADB of the National Health Act 1953) as shown in this compilation is amended as indicated in the Tables below.\n\n> Note: > Note: Table of Instruments\n\n| Title | Date of FRLI Registration | Date ofcommencement | Application, saving ortransitional provisions |\n| -------------- | ------------------------------ | ------------------- | --------------------------------------------- |\n| PB 74 of 2009 | 30 July 2009 (see F2009L03001) | 31 July 2009 | |\n| PB 95 of 2009 | 29 Sept 2009 (see F2009L03722) | 30 Sept 2009 | — |\n| PB 105 of 2009 | 1 Oct 2009 (see F2009L03737) | 1 Oct 2009 | — |\n| PB 12 of 2010 | 25 Jan 2010 (see F2010L00185) | 26 Jan 2010 | — |\n\n> Note: > Note: Table of Amendments\n\n```html\n

ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted

Provision affected

How affected

Schedule 1

Schedule 1.................

am. PB 95 and 105 of 2009; PB 12 of 2010

Schedule 2

Schedule 2.................

am. PB 95 and 105 of 2009; PB 12 of 2010

\n```","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":2532},"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"The instrument maintains its original narrow scope of declaring weighted average disclosed prices for specific pharmaceutical benefits as permitted by section 99ADB of the National Health Act 1953. It simply updates the price list from the previous determination (PB 18 of 2009)."},"complexity_factors":["Extensive tabular schedules listing pharmaceutical items by chemical name, form, strength, and specific brand","Technical terminology requiring knowledge of the PBS price disclosure framework under section 99ADB of the National Health Act 1953","Cross-referencing mechanism between Schedule 1 (reference brands) and Schedule 2 (equivalent brands with same drug and administration route)"],"plain_english_summary":"This determination sets the maximum government subsidy (weighted average disclosed prices) under the PBS for three medicines—Carvedilol, Fluconazole and Vancomycin—applying those benchmark prices to named brands and equivalent generics. It directly affects how much the government pays pharmacies and what patients may owe if pharmacies buy above the WADP, incentivising price competition between brands and generics."},"flash_summary":{"complexity_score":3,"scope_assessment":{"changed":true,"description":"The Determination's legal role — to set weighted average disclosed prices under s.99ADB(4)–(5) — remains unchanged, but its operational scope (the particular brands and prices) was altered by subsequent amendments (PB 95 of 2009, PB 105 of 2009 and PB 12 of 2010), which updated Schedule 1 and Schedule 2 entries and replaced the earlier PB 18 of 2009 instrument (see Determination clause 2 and Notes: Table of Amendments)."},"complexity_factors":["Direct cross‑reference to National Health Act 1953 s.99ADB(4) and (5) to create legal effect (see Determination clauses 3–4).","Relies on two schedules listing multiple drugs, dosage forms, brands and precise monetary amounts (many entries and variants).","Administrative complexity from amendment history (PB 95/2009, PB 105/2009, PB 12/2010) requiring updates to schedules and potential transitional handling (see Notes: Table of Instruments and Table of Amendments).","Mapping rule in clause 4 that extends prices from listed brands to all brands with the same drug and manner of administration — requires correct product matching by administrators and suppliers.","Precision of numeric price entries increases compliance burden (accurate recording, invoicing, reimbursement calculations)."],"plain_english_summary":"This instrument sets specific \"weighted average disclosed prices\" for named branded pharmaceutical items (Schedule 1) and declares the same price for any other brand with the same active drug and administration (Schedule 2). It commenced 31 July 2009 and replaced an earlier instrument. It matters because those declared prices — made under s.99ADB of the National Health Act 1953 — determine the official price reference used by suppliers, pharmacies and administrators when applying the Act."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-act-1953-determination-under-section-99adb-weighted-average-disclosed-price-no-pb-74","history":"/api/acts/national-health-act-1953-determination-under-section-99adb-weighted-average-disclosed-price-no-pb-74/history","analysis":"/api/acts/national-health-act-1953-determination-under-section-99adb-weighted-average-disclosed-price-no-pb-74/analysis","conflicts":"/api/acts/national-health-act-1953-determination-under-section-99adb-weighted-average-disclosed-price-no-pb-74/conflicts","importantCases":"/api/acts/national-health-act-1953-determination-under-section-99adb-weighted-average-disclosed-price-no-pb-74/important-cases","documents":"/api/acts/national-health-act-1953-determination-under-section-99adb-weighted-average-disclosed-price-no-pb-74/documents"}}